Four reasons to invest in AcuCort
-
-
Innovative product
Zeqmelit® addresses a large patient need in acute and severe allergic reactions. The drug is a fast-soluble mouth film that is easy to carry with you and easy to put on the tongue, without the need for water.
-
Large market
About 20% of the world’s population suffers from allergic symptoms. The potential market for Zeqmelit™ is estimated to be worth more than USD 3 billion.
-
Low development risk
Zeqmelit® is fully developed and approved in Sweden, Denmark, Norway and Finland. The registration processes are ongoing in the rest of the EU.
-
Competent and experienced team
Company management and the Board of Directors have broad and deep experience of commercializing new drugs.
-